Concord Biotech Limited vs Gland Pharma Limited
Last updated: 22 October 2026
Concord Biotech vs Gland Pharma: A MoneyDock Comparison
Concord Biotech Limited and Gland Pharma Limited are prominent players in the Indian pharmaceutical sector, making them natural candidates for comparison for investors tracking the healthcare space. Concord Biotech is known for its fermentation-based products, focusing on immunosuppressants and oncology. Gland Pharma, on the other hand, specializes in injectables, including complex injectables, and has a significant presence in global markets. Both companies operate in critical segments of the pharmaceutical industry, offering distinct investment propositions. This comparison will delve into their recent performance and key metrics to help Indian investors make informed decisions, considering their current market standing and historical returns.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited (CONCORDBIO.NS) | Gland Pharma Limited (GLAND.NS) |
|---|---|---|
| Current Price | ₹1270.70 | ₹2850.40 |
| 52-Week High | ₹1579.40 | ₹3150.60 |
| 52-Week Low | ₹1014.80 | ₹1596.80 |
| 1-Year Return | -7.88% | 71.25% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
When we assess these two pharmaceutical giants, Gland Pharma Limited clearly emerges as the winner in terms of recent returns. Its impressive 1-Year Return of 71.25% significantly outperforms Concord Biotech Limited, which recorded a negative return of -7.88% over the same period. This stark difference highlights Gland Pharma's strong upward momentum and investor confidence in its recent performance, while Concord Biotech has faced headwinds.
Regarding stability and price movement, Gland Pharma's current price of ₹2850.40 is closer to its 52-Week High of ₹3150.60 than its 52-Week Low of ₹1596.80. This suggests a sustained positive trend and resilience, indicating that the stock has maintained much of its gains. Conversely, Concord Biotech's current price of ₹1270.70, while above its 52-Week Low of ₹1014.80, is notably below its 52-Week High of ₹1579.40. This suggests a period of correction or consolidation for Concord Biotech following its peak.
Valuation metrics like Trailing P/E and Market Cap are unfortunately not available for both companies in the provided data. This limits a direct comparison on traditional valuation multiples. However, based solely on price performance and movement relative to 52-week highs and lows, Gland Pharma demonstrates stronger current momentum and a more robust recovery from its yearly low, indicating greater investor favor and potentially perceived stability over the past year. Concord Biotech, despite being a significant player, shows a less favorable short-term price trajectory. Investors looking at price stability and strong positive returns would find Gland Pharma's recent performance more appealing.
MoneyDock Verdict
For Aggressive Investors: Gland Pharma Limited appears more attractive. Its significant 1-Year Return of 71.25% indicates strong growth momentum, potentially offering higher upside for those comfortable with calculated risks. Concord Biotech's negative return suggests it might be in a corrective phase, which aggressive investors might eye for a turnaround, but Gland Pharma holds the current edge.
For Conservative Investors: Neither stock offers a clear 'safe' bet based solely on the provided data, especially without P/E and Market Cap. However, Gland Pharma's strong positive return suggests it has been a more stable performer for investors over the past year compared to Concord Biotech's negative returns. Conservative investors might prefer waiting for more comprehensive valuation data for both, or consider Gland Pharma for its demonstrated strength, albeit with an understanding of market volatility.
For Long-Term SIP Investors: Gland Pharma's consistent upward trend and strong 1-Year Return could make it a compelling option for SIP investors looking to accumulate shares in a performing asset over time. Concord Biotech, with its recent negative performance, would require a deeper dive into its fundamentals and future growth prospects to ascertain its long-term SIP suitability, as its current trajectory suggests a more challenging period for sustained returns.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.